Idacta-mab INT-001 represents a exciting medicinal strategy for managing certain hematologic tumors. This particular antibody demonstrates the distinct process of function, particularly interacting with the CD38 antigen, a membrane antigen expressed widely on various blood cells. Preliminary patient trials aiming to evaluate the tolerability and po

Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement within targeted cancer therapy. This innovative antibody-drug conjugate pairs a monoclonal antibody specifically directed at HER-2 expressing cells with the potent anticancer payload, deruxtecan. The process of action entails the antibody's ability to bind to t